Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec Makes A Case For Neurology

This article was originally published in The Pink Sheet Daily

Executive Summary

Management laid out Biogen's neurology pipeline to investors Nov. 30, but most of the drugs are in early development.

You may also be interested in...

ALS TDI Advances Two Drugs Toward The Clinic

The non-profit research organization, focused on the development of drugs for the treatment of ALS, is making clinical progress on two drugs, one of which is Novartis’ Gilenya.

Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis

Saying his new company is spread "a mile wide and an inch deep," Biogen Idec Inc.'s CEO George Scangos, PhD, affirmed Nov. 3 that the big biotech firm will drastically pare its pipeline, cut 13% of staff, and refocus its efforts around its historic strength – its multiple sclerosis franchise.

UCB Provides Synosia With Its First Out-Licensing Deal And Leads Its $30M Series C Funding

UCB gains rights to Synosia's potential Parkinson's disease therapies in deal that could be worth $725 million in milestones

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts